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Background: The purposes of this study were to estimate the prevalence of recent influenza
vaccination, to identify sociodemographic risk factors and reasons for non-vaccination, and
to examine the association between influenza vaccination and respiratory medication use,
among individuals with asthma and COPD in Canada.
Methods: Data from the 2003 Statistics Canada Canadian Community Health Survey
(nZ 134,072, age 12e80þ years) were analyzed. All data were based on self-report.
Results: An estimated 36.3% and 47.9% of individuals with asthma and COPD, respectively,
were immunized for influenza within the last year in 2003. These vaccination rates were
relatively lower than those seen with other non-respiratory health conditions. Respondents
thinking that influenza vaccination was not necessary was the most frequent reason cited
for non-vaccination among individuals with asthma and COPD. Men, non-Ontarians, younger
age groups, current smokers, and those without a family doctor were less likely to be
vaccinated among individuals with asthma and COPD. After controlling for potential socio-
demographic confounders, among individuals with asthma, those vaccinated for influenza
had significantly greater odds of using inhalers/nebulizers (ORZ 1.8, 95% CIZ 1.3e2.4).
No other significant medication use associations were observed among individuals with
asthma and COPD.
Conclusions: Recent self-reported influenza vaccination rates among individuals with asthma
and COPD were relatively low. Influenza vaccination was not associated with decreasedctive pulmonary disease; NACI, National Advisory Committee on Immunization; CCHS, Canadian
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Influenza vaccination and lung disease 51respiratory medication use among individuals with asthma and COPD, suggesting that vacci-
nation may not help prevent exacerbations. More research is needed to fully clarify the
role of influenza vaccination in chronic respiratory disease, particularly asthma, to justify
policies of mass-immunization.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Influenza infection is estimated to account for 10e30% of
exacerbations of asthma1e3 and chronic obstructive
pulmonary disease (COPD).4e8 Health Canada’s National
Advisory Committee on Immunization (NACI) recommends
annual influenza vaccination for persons with asthma and
COPD regardless of age and disease severity.9 Most
countries,10 and global asthma11 and COPD12 guidelines
make similar recommendations. Despite universal
recommendation, influenza vaccination among individuals
with asthma and COPD remains low internationally.13e18
In Canada, we have minimal information on the preva-
lence of influenza vaccination, as well as sociodemo-
graphic risk factors and reasons for non-vaccination, in
asthma and COPD.19
Although influenza vaccination appears to be effective
in reducing acute respiratory illness in healthy adults20,21
and the elderly,22e25 the effectiveness of influenza vacci-
nation specifically in those with asthma and COPD is not as
clear. Several studies have shown that influenza vaccina-
tion reduces morbidity and mortality in those with
COPD,7,8,26e28 while other studies show no significant
benefit of vaccination.29e32 Most studies to date have found
no beneficial effect of influenza vaccination in those with
asthma,30,33e35 and two trials have even suggested
harm.36,37
The purposes of this study were to estimate the preva-
lence of recent influenza vaccination, to identify socio-
demographic risk factors and reasons for non-vaccination,
and to examine the association between influenza vacci-
nation and respiratory medication use (as a marker of
influenza vaccination effectiveness), among individuals
with asthma and COPD in Canada.
Methods
Data
This study was conducted with data from the public use
microdata file for the 2003 Canadian Community Health
Survey (CCHS). The CCHS is an ongoing survey conducted by
Statistics Canada that collects cross-sectional self-reported
sociodemographic and health data on Canadians. A detailed
description of the survey design and methodology appears
elsewhere.38e40 Survey respondents included household
residents over aged 12 years in all provinces and territories,
with the exclusion of individuals living on Indian Reserves and
Crown Lands, institutional residents, full-time members of
the Canadian Armed Forces, residents of remote regions of
Canada, and homeless persons.38 Data were collected
between January and December 2003.38 The response rate
was 80.7%, yielding a total sample of 134,072 respondents.38Asthma and COPD
Only those respondents with self-reported asthma and
COPD were included in the analysis. We categorized
respondents as having COPD if they reported affirmatively
to having chronic bronchitis or emphysema. The survey
classed respondents as having the specified health condi-
tions only if they reported that it lasted or was expected to
last for 6 months or longer, and that it had been diagnosed
by a health professional.
Influenza vaccination
The CCHS asked, ‘‘Have you ever had a flu shot?’’. Among
those respondents who had a flu shot the following question
was asked, ‘‘When did you last have your flu shot?’’; with
possible responses of ‘‘less than 1 year ago; 1 year to less
than 2 years ago; 2 years ago or more; don’t know; and
refused’’. Those who responded affirmatively to having had
the flu shot less than 1 year ago were classed as having
received influenza vaccination within the past year, while
all others were classed as not having received influenza
vaccination within the past year. Among individuals over
age 50 years who did not have influenza vaccination in the
past year, the survey asked about reasons for non-recent
vaccination including, ‘‘have not gotten around to it’’; ‘‘did
not think it was necessary’’; ‘‘doctor did not think it was
necessary’’; ‘‘bad reaction to previous shot’’; ‘‘fear’’; and
others (see footnote in Table 2).
Sociodemographic and medication use variables
All sociodemographic and medication use variables were
based on self-report. The following sociodemographic
variables were examined: sex, province, age, race, immi-
gration status, education level, income source, income
level, whether or not children under age 12 resided in the
household, smoking status, whether or not the respondent
had a family doctor, and whether or not the respondent had
insurance for prescription medications.
While a variety of outcome measures such as medication
use, mortality, hospitalization, presence of respiratory symp-
toms, diagnosis of pneumonia, and spirometry have been used
in previous studies examining the effectiveness of influenza
vaccination inasthmaandCOPD,medicationuse is theonlyone
that is available for potential study in the CCHS. We assume
that if influenza vaccination protects against acute respiratory
illness, individuals who receive vaccination should require less
medications such as inhalers, cough remedies, antibiotics, and
steroids that may be used in respiratory exacerbations. The
CCHS asked, ‘‘In the past month, did you take asthma medi-
cations like inhalers or nebulizers; cough or cold remedies;
penicillin or other antibiotics; and steroids?’’ Those who
Table 1 Frequency of influenza vaccination within the
previous year for selected chronic conditions.
Health condition Total
number
Number (%)
vaccinated
Asthma 11,938 4334 (36.3)
COPD 5532 2649 (47.9)
Diabetes 7749 4345 (56.1)
Congestive heart failure 1657 991 (59.8)
Any Cancer 2821 1500 (53.2)
Asthma, plus
at least one of the following
comorbidities: diabetes,
congestive heart failure,
and any cancer
963 621 (64.5)
COPD, plus
at least one of the following
comorbidities: diabetes,
congestive heart failure,
and any cancer
1040 651 (62.6)
Table 2 Frequency of reasons for not receiving influenza
vaccination within the past year among individuals with
asthma and COPD over the age of 50 years who were not
vaccinated in the past year.
Reason for
non-vaccinationa
Asthma
number (%)
COPD
number (%)
Didn’t think
it was necessary
681 (54.5) 527 (48.8)
Have not gotten
around to it
217 (17.4) 170 (15.8)
Bad reaction
to previous shot
173 (13.9) 195 (18.2)
Doctor didn’t
think it was necessary
80 (6.4)b 77 (7.2)b
Fear 70 (5.6)b 54 (5.0)b
a Data for other reasons for non-vaccination, including
personal/family responsibilities, not available at time reques-
ted, not available at all in area, waiting time too long, trans-
portation problems, language problems, cost, didn’t know
where to go, unable to leave the house because of a health
problem, and other are not presented because according to
Statistics Canada data release guidelines 35 they are unreliable
estimates given that they are based on <30 responses.
b Coefficient of variation between 16.6% and 33.3%, interpret
estimate with caution given high sampling variability.
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Statistical methods
All analyses were performed on SAS version 9.1. Cross-
tabulations were calculated to estimate the prevalence of
influenza vaccination within the past year among individ-
uals with asthma and COPD with and without selected
comorbidities (i.e. diabetes, congestive heart failure, and
cancer), as well as the prevalence of reasons for non-
vaccination among the over aged 50 years subgroup with
asthma and COPD. We also calculated the prevalence of
influenza vaccination within the past year among survey
respondents with self-reported diabetes, cancer, and
congestive heart failure, which are examples of other
chronic health conditions for which NACI recommends
mass-vaccination, in order to compare the vaccination rate
between respiratory and non-respiratory health conditions.
Cross-tabulations and multiple logistic regressions were
used to examine the association between recent influenza
vaccination among individuals with asthma and COPD and
the selected sociodemographic and medication use vari-
ables. Sex, age, province, income source, smoking status,
and whether or not the respondent had a family doctor (and
whether or not the respondent had insurance for medica-
tions for individuals with asthma only) were included in
a regression model to control for their potentially con-
founding effects on the odds of self-reported medication
use, since all these variables were found to be independent
risk factors for non-vaccination (see Tables 3 and 4).
The CCHS uses a complex sampling design, employing
stratification and multi-stage clustering techniques, and
unequal probabilities of selecting respondents. To account
for the unequal probabilities of selecting respondents, all
results were weighted using the sample weights provided in
the public use microdata file. All sample weights were re-
scaled prior to each analysis by dividing the original weight
by the average weight of respondents included in the
specific analysis, according to Statistics Canada guide-
lines.38 To account for the effects of stratification and
clustering, all confidence intervals were calculated using
bootstrap resampling techniques with a set of 500 bootstrap
weights created by Statistics Canada.
Results
Of the 134,072 survey respondents, 11,938 (8.9%) self-
reported asthma and 5532 (4.1%) self-reported COPD. An
estimated 36.3% of individuals with asthma and 47.9% of
individuals with COPD self-reported influenza vaccination
within the past year. These influenza vaccination rates
were lower than that seen in other chronic conditions for
which annual vaccination is also recommended (see
Table 1). Vaccination rates were higher in both asthma
and COPD in the presence of comorbidities. Among
individuals with asthma and COPD over aged 50 years
who were not vaccinated within the past year, the most
frequently cited reasons for non-vaccination were ‘didn’t
think it was necessary’, followed by ‘have not gotten
around to it’ and ‘bad reaction to previous shot’. A smallfraction reported that their ‘doctor didn’t think it was
necessary’, while other reasons for non-vaccination were
negligible (see Table 2).
Men, non-Ontarians, younger age groups, current
smokers, and those without a family doctor were less likely
to have received influenza vaccination within the past year
among individuals with asthma and COPD. Also among
individuals with asthma, those without insurance for
prescription medication were less likely to have received
influenza vaccination (see Tables 3 and 4).
Table 3 Adjusteda odds for reporting influenza vaccination in the past year among individuals with asthma (nZ 11,938).
Number % Not
vaccinated
(nZ 7664)
% Vaccinated
(nZ 4334)
Adjusted OR (95% CI)
for reporting
vaccination
Sex
Male 5002 68.1 31.9 1.0
Female 6936 60.5 39.5 1.3 (1.1e1.4)
Area of Residence
Atlantic Canada 979 67.5 32.5 0.5 (0.4e0.6)
Quebec 2914 69.0 31.0 0.5 (0.4e0.5)
Ontario 4592 55.5 44.5 1.0
Western Canada 3424 69.1 30.9 0.5 (0.4e0.6)
Age group
<40 6299 78.6 21.4 0.6 (0.5e0.7)
40e49 1915 65.4 34.6 1.0
50e69 2644 42.6 57.4 2.1 (1.7e2.6)
>70 1080 25.6 74.4 3.4 (2.6e4.6)
Race
Caucasian 10,573 63.5 36.5 1.0
Visible minority 1365 65.3 34.7 1.1 (0.9e1.4)
Immigrant
Yes 1467 53.2 46.8 0.9 (0.7e1.2)
No 10,470 65.2 65.2 1.0
Education level
<Secondary graduation 3823 62.0 38.0 1.0 (0.8e1.2)
Secondary graduation 1938 68.2 31.8 0.8 (0.7e1.1)
Some post-secondary 927 70.2 29.8 1.0
Post-secondary graduation 4980 62.2 38.8 1.1 (0.9e1.4)
Not stated 267
Income source
Employment 8273 70.5 29.5 1.0
Unemployment insurance/
worker’s compensation/welfare
579 66.5 33.5 1.3 (0.9e1.7)
Senior’s benefits 1693 29.2 70.8 1.9 (1.6e2.4)
Other 407 60.2 38.8 1.1 (0.8e1.6)
Not stated 987
Income adequacy
Lowest income 399 59.9 40.1 1.1 (0.7e1.7)
Lower middle 792 61.9 38.1 0.8 (0.6e1.1)
Middle 2125 58.0 42.0 1.1 (0.9e1.3)
Upper middle 3134 61.9 38.1 1.0
Highest 3358 68.4 31.6 0.8 (0.7e1.0)
Not stated 2129
Children< age 12 in household
Yes 2922 75.3 24.7 0.9 (0.7e1.0)
No 9017 59.9 40.1 1.0
Smoking status
Current smoker 2855 71.3 28.7 0.8 (0.7e0.9)
Former/never-smoker 9083 61.3 38.7 1.0
Has family doctor
Yes 10,600 61.0 39.0 2.2 (1.7e2.9)
No 1338 85.4 14.6 1.0
Has insurance for medications
Yes 9443 62.2 37.8 1.3 (1.1e1.6)
No 2495 70.0 30.0 1.0
a Adjusted for other variables listed in table.
Table 4 Adjusteda odds for reporting influenza vaccination in the past year among individuals with COPD (nZ 5532).
Number % Not vaccinated
(%) (nZ 2883)
% Vaccinated
(nZ 2649)
Adjusted OR (95% CI)
for reporting vaccination
Sex
Male 2251 55.1 44.9 1.0
Female 3281 50.0 50.0 1.4 (1.2e1.7)
Area of Residence
Atlantic Canada 547 55.1 44.9 0.6 (0.5e0.8)
Quebec 1380 55.0 45.0 0.6 (0.5e0.8)
Ontario 2225 49.4 50.6 1.0
Western Canada 1370 52.3 47.7 0.8 (0.6e1.0)
Age group
<40 1292 80.0 20.0 0.6 (0.4e0.8)
40e49 807 66.4 33.6 1.0
50e69 2125 43.2 56.8 2.0 (1.4e2.8)
>70 1307 30.3 69.7 2.4 (1.6e3.6)
Race
Caucasian 5037 50.6 49.4 1.0
Visible minority 495 67.2 32.8 0.7 (0.5e1.1)
Immigrant
Yes 839 52.7 47.3 0.9 (0.6e1.2)
No 4693 48.9 51.1 1.0
Education level
<Secondary graduation 2111 47.5 52.5 1.3 (0.9e1.9)
Secondary graduation 903 55.2 44.8 1.4 (0.9e2.0)
Some post-secondary 307 64.1 35.9 1.0
Post-secondary graduation 2071 53.6 46.4 1.4 (0.9e2.0)
Not stated 140
Income source
Employment 2619 66.5 33.5 1.0
Unemployment insurance/
worker’s compensation/welfare
390 56.2 43.8 1.5 (1.0e2.2)
Senior’s benefits 1804 30.3 69.7 2.1 (1.6e2.7)
Other 257 46.3 53.7 1.6 (1.0e2.5)
Not stated 462
Income adequacy
Lowest income 237 44.3 55.7 1.3 (0.8e1.9)
Lower middle 624 50.6 49.4 0.8 (0.6e1.1)
Middle 1288 49.8 50.2 0.8 (0.6e1.1)
Upper middle 1460 50.7 49.3 1.0
Highest 1001 60.8 39.2 0.8 (0.6e1.1)
Not stated 992
Children< age 12 in household
Yes 845 75.4 24.6 0.7 (0.5e1.1)
No 4687 47.9 52.1 1.0
Smoking status
Current smoker 2057 63.4 36.7 0.6 (0.5e0.8)
Former/never-smoker 3475 45.5 54.5 1.0
Has family doctor
Yes 5086 49.5 50.5 3.0 (2.1e4.3)
No 446 82.1 17.9 1.0
Has insurance for medications
Yes 4332 50.6 49.4 1.2 (0.9e1.4)
No 1210 57.6 42.4 1.0
a Adjusted for other variables listed in table.
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Influenza vaccination and lung disease 55Among individuals with asthma, those reporting recent
influenza vaccination were significantly more likely to have
used inhalers/nebulizers in the past month. No significant
associations were observed between influenza vaccination
and use of cough/cold remedies, antibiotics, and steroids
among those with asthma. Adjusting for potential socio-
demographic confounders did not alter these results (see
Table 5). Among individuals with COPD, no significant
associations were observed between influenza vaccination
and any of the selected medications. Adjusting for poten-
tial sociodemographic confounders did not alter these
results (see Table 6).Discussion
A minority of Canadians with asthma and COPD in 2003 self-
reported recent influenza vaccination (36.3% and 47.9%,
respectively). These vaccination rates are relatively lower
than those seen among individuals with other chronic non-
respiratory health conditions. Vaccination rates were
higher when comorbidities were present in asthma and
COPD. Respondents thinking that influenza vaccination was
not necessary was the most frequent reason cited for non-
vaccination among individuals with asthma and COPD. Men,
non-Ontarians, younger age groups, current smokers, those
without a family doctor, and those without insurance for
prescription medications were identified as independent
risk factors for non-recent influenza vaccination among
individuals with asthma and COPD. After controlling for
potential sociodemographic confounders, among those with
asthma, those self-reporting recent influenza vaccinationTable 5 Crude and adjusteda odds of reporting selected
medication use within the past month among individuals
with asthma (nZ 11,938) by influenza vaccination status.
Number
(%)b
Crude OR
(95% CI)
Adjusted
OR (95% CI)
Inhalers/
nebulizers
973
Vaccinated 69.4% 2.1 (1.6e2.7) 1.8 (1.3e2.4)
Not vaccinated 57.6% 1.0 1.0
Cough/cold
remedies
484
Vaccinated 27.2% 0.9 (0.7e1.1) 1.3 (0.9e1.8)
Not vaccinated 30.0% 1.0 1.0
Antibiotics 240
Vaccinated 17.6% 1.4 (1.1e2.1) 1.5 (1.0e2.3)
Not vaccinated 12.4% 1.0 1.0
Steroids 78
Vaccinated 6.9% 2.0 (1.2e3.4) 1.4 (0.7e2.5)
Not vaccinated 3.4% 1.0 1.0
a Adjusted for sex, age, province, income source, smoking
status, and whether or not the respondent had a family doctor
and insurance for medications.
b Numbers represent respondents who reported use of the
specificmedication. Percentages represent the percent individuals
by vaccination status who reported use of the specific medication.were roughly two times more likely to have used inhalers/
nebulizers in the past month. No other significant medica-
tion use associations were observed among individuals with
asthma or COPD.
This study has several limitations which must be
acknowledged. The cross-sectional nature of the data does
not make it possible to draw causal inferences. The findings
were based entirely on self-reported measures, thereby
potentially introducing recall and social desirability biases.
We were limited to studying medication use as the only
potential measure of influenza vaccination effectiveness,
since the CCHS does not contain data on other outcomes
(e.g. mortality, hospitalization, or diagnosis of respiratory
infection). The fact that self-reported medication use is
limited to the preceding month, and that we are relating
this to influenza vaccination within the past year, is also
a limitation. If significant numbers of survey respondents
self-reported medication use prior to the time of their
vaccination, this would complicate interpretation of any
observed medication use associations. Given that the
survey data were collected over twelve months, it is also
possible that influenza vaccination may have lost its
intended protective effects in individuals who had a signif-
icant time lag between vaccination and survey adminis-
tration. The survey also does not specify what time of year
data were collected for each particular respondent, so
analyzing the data specifically from the ‘influenza season’
is not possible. Another limitation is the assumption that
reported medication use is solely for respiratory-health
purposes. It is possible that, for example, reported antibi-
otic and steroid use may be related to the treatment of
non-respiratory infections or other conditions thatTable 6 Crude and adjusteda odds of reporting selected
medication use within the past month among individuals
with COPD (nZ 5532) by influenza vaccination status.
Number
(%)b
Crude OR
(95% CI)
Adjusted
OR (95% CI)
Inhalers/
nebulizers
291
Vaccinated 40.6% 1.7 (1.2e2.6) 1.6 (1.0e2.5)
Not vaccinated 28.1% 1.0 1.0
Cough/cold
remedies
245
Vaccinated 23.8% 0.6 (0.4e0.9) 0.8 (0.5e1.3)
Not vaccinated 35.9% 1.0 1.0
Antibiotics 145
Vaccinated 19.2% 1.3 (0.8e2.2) 1.7 (0.9e3.2)
Not vaccinated 15.3% 1.0 1.0
Steroids 57
Vaccinated 8.2% 1.5 (0.6e3.2) 1.7 (0.6e4.7)
Not vaccinated 5.5% 1.0 1.0
a Adjusted for sex, age, province, income source, smoking
status, and whether or not the respondent had a family doctor.
b Numbers represent respondents who reported use of the
specific medication. Percentages represent the percent indi-
viduals by vaccination status who reported use of the specific
medication.
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can also be argued that one may not expect all of the
medications studied here (e.g. antibiotics) to be prescribed
in a viral-associated respiratory exacerbation, if suspected.
The survey does not differentiate between classes of
‘inhaler/nebulizer’ medications (i.e. bronchodilators,
anticholinergics, and corticosteroids) and between types of
‘steroids’ (i.e. inhaled, systemic, and topical). We also had
no means by which to control for the potentially con-
founding effects of respiratory disease severity and
compliance with treatment on our medication use results.
Similar to our national Canadian findings, the influenza
vaccination prevalence rates among individuals with
asthma and COPD in Europe and the US are also low, in the
range of 30e50%.13e18 The finding of lower vaccination
rates among those with chronic respiratory disease versus
other chronic health conditions has been reported in the US
as well.13 Our finding of respondents thinking vaccination
was not necessary as a major reason for non-vaccination is
consistent with results from a recent European study of
individuals with chronic lung disease.18 This result suggests
the need for greater patient education in future vaccina-
tion strategies. Physician education, fear, and vaccination
access issues do not significantly affect influenza vaccina-
tion coverage in Canada.
In keeping with our finding that Ontario has higher
influenza vaccination rates among individuals with asthma
and COPD than other parts of the country, an Ontario survey
of individuals with COPD reported 90% received annual
influenza vaccination.19 Although all Canadian provinces and
territories, with the exception of Prince Edward Island, now
have publicly funded influenza vaccination for all individuals
with chronic pulmonary and cardiac conditions,41 public
awareness and government promotion of Ontario’s inter-
nationally unique, publicly funded, influenza vaccination
programfor theentirepopulation aged6monthsor oldermay
explain why vaccination rates are higher in Ontario,42 even
among those with chronic respiratory disease.
Similar to other studies,16e18,43 we have identified
younger age groups, current smokers, and those with less
access to family physicians as independent risk factors for
non-vaccination among individuals with asthma and COPD.
The fact that older persons with chronic respiratory disease
were more likely to receive influenza immunization than
their younger counterparts suggests that individuals with
chronic respiratory disease may receive vaccination as
a result of entering the age group of universal vaccination
in most Canadian provinces (i.e. >65 years), instead of as
a result of their disease status. This is consistent with
a previous analysis of vaccination strategies that suggests
that strategies that select patients by age group rather than
disease group are more effective at increasing vaccination
coverage.44 The finding that current smokers were less
likely to receive influenza vaccination is important since
smokers with chronic respiratory disease are at increased
risk of respiratory exacerbations.45e47 The fact that lack of
a family physician was associated with non-vaccination is
not surprising given that family physicians play a prominent
role in administering influenza vaccination in Canada.48,49
In contrast to previous studies,16e18,43 we have identified
gender differences in influenza vaccination among individ-
uals with chronic respiratory disease.Self-reported usage of medications that may be
prescribed in acute respiratory exacerbations was not
decreased among individuals with COPD who were immu-
nized, and among individuals with asthma who were
immunized greater self-reported use of inhalers/nebulizers
was found, suggesting that influenza vaccination may not
help prevent respiratory exacerbations. Several studies
have shown that influenza vaccination reduces mortality,
hospitalization, and pneumonia in those with COPD,7,8,26e28
but other studies show no significant benefits of vacci-
nation.29e32 Among studies that do show benefit in COPD,
there is also discrepancy as to whether influenza vaccina-
tion protects against all-cause or just influenza-associated
acute respiratory illness.8,28 With respect to asthma, most
studies to date have found no beneficial effect of influenza
vaccination.30,33e35 In one cohort study of children with
asthma, the vaccine group had a significantly increased risk
of asthma-related emergency department and clinic visits
after controlling for potential confounders.36 Another study
reported a fourfold increased risk of asthma exacerbation
in children 18e35 months old with asthma after intranasal
influenza vaccination.37
In conclusion, recent self-reported influenza vaccina-
tion rates among individuals with asthma and COPD in
Canada in 2003 were relatively low (36% and 48%,
respectively) compared to individuals with other non-
respiratory chronic illnesses. Risk factors and reasons for
non-vaccination were identified. Given the low prevalence
of influenza vaccination, and the fact that the most
common reason for non-vaccination was respondents
reporting vaccination as simply not being necessary,
demonstrating and disseminating evidence of influenza
vaccination efficacy is needed to help increase public
awareness of the potential merits of influenza vaccination
in chronic respiratory disease. However, influenza vacci-
nation was not associated with decreased self-reported
medication use among individuals with asthma and COPD,
suggesting that influenza vaccination may not help
prevent acute respiratory exacerbations, although there
are several limitations associated with this analysis
including the potentially confounding effects of respira-
tory disease severity. More research is needed to clarify
the role of influenza vaccination in chronic respiratory
disease, particularly asthma, before governments can
confidently pursue policies of mass-immunization.Conflict of interest
Neither author has any conflict of interests to declare.
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